255.77
Schlusskurs vom Vortag:
$255.64
Offen:
$262.54
24-Stunden-Volumen:
180.35K
Relative Volume:
0.37
Marktkapitalisierung:
$26.40B
Einnahmen:
$3.81B
Nettoeinkommen (Verlust:
$-644.79M
KGV:
-40.99
EPS:
-6.24
Netto-Cashflow:
$-669.77M
1W Leistung:
+4.44%
1M Leistung:
-6.92%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Beigene Ltd Adr Stock (ONC) Company Profile
Firmenname
Beigene Ltd Adr
Sektor
Branche
Telefon
13459494123
Adresse
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Vergleichen Sie ONC mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
2023-09-12 | Eingeleitet | Macquarie | Outperform |
2023-08-17 | Eingeleitet | Jefferies | Buy |
2023-07-17 | Eingeleitet | Citigroup | Buy |
2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
2021-10-12 | Eingeleitet | Bernstein | Outperform |
2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
2021-03-08 | Eingeleitet | China Renaissance | Buy |
2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beigene Ltd Adr Aktie (ONC) Neueste Nachrichten
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins US patent dispute over cancer drug - Investing.com
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
Finanzdaten der Beigene Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beigene Ltd Adr-Aktie (ONC) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Sale |
242.66 |
41,760 |
10,133,595 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):